Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IKT-001

Small molecule · developed by Inhibikase Therapeutics

Phase 3 Most advanced trial

IKT Developer

1 Registered trials

What is IKT-001?

IKT-001 is an investigational small-molecule drug studied in Pulmonary Arterial Hypertension.

At a glance

Drug type: Small molecule
Therapy area: Respiratory
Developer: Inhibikase Therapeutics (IKT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07365332	Phase 3	Pulmonary Arterial Hypertension	Recruiting	IKT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pulmonary Arterial Hypertension

More from Inhibikase Therapeutics

IkT-001Pro Phase 2

Sources

ClinicalTrials.gov NCT07365332

Updated Oct 3, 2026. Something wrong or missing? Report it on the IKT page.

Follow IKT, the company behind IKT-001

See IKT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IKT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z